Progression-free survival (PFS), defined as the time of stage III diagnosis to the time of progression, and overall survival (OS), defined as the time of stage III diagnosis to the time of death or last follow-up, were compared among patients with different levels of tumor HLA-1 expression and CD8 infiltration. The gene discussed is CD8A; the disease is neoplasm.